Global Age-Related Macular Degeneration Market Outlook
The global age-related macular degeneration market size was valued at USD 2.04 billion in 2023, driven by an increase in the prevalence of age-related macular diseases across the globe. The market size is anticipated to grow at a CAGR of 8.9% during the forecast period of 2024-2032 to achieve a value of USD 4.40 billion by 2032.
Age-Related Macular Degeneration: Introduction
Age-related macular degeneration (AMD) is a progressive eye condition that primarily affects individuals aged 50 and older, leading to the deterioration of the macula, the central part of the retina responsible for sharp, central vision. AMD is a leading cause of vision loss among older adults, significantly impacting the ability to perform everyday activities such as reading, driving, and recognizing faces. There are two main types of AMD: dry (atrophic) and wet (neovascular).
Dry AMD is characterized by the thinning of the macula and the accumulation of drusen (yellow deposits), while wet AMD involves abnormal blood vessel growth under the retina, leading to leakage and scarring. Early detection and management through lifestyle changes, nutritional supplements, and medical treatments can slow the progression of AMD and preserve vision.
Get a Free Sample Report with Table of Contents –https://www.expertmarketresearch.com/reports/age-related-macular-degeneration-market/requestsample
Key Trends in the Global Age-Related Macular Degeneration Market
Some key trends in the market include:
- Advancements in Treatment Options: Significant progress in the development of novel therapies, such as anti-VEGF (vascular endothelial growth factor) injections, gene therapy, and stem cell therapy, is transforming AMD treatment. These innovative treatments aim to slow disease progression, improve vision, and enhance patients’ quality of life.
- Increasing Prevalence of AMD: The rising aging population worldwide is leading to an increase in the prevalence of AMD. As life expectancy continues to grow, the number of individuals affected by AMD is expected to rise, driving demand for effective treatments and diagnostic tools.
- Technological Innovations in Diagnostics: Advances in imaging technologies, such as optical coherence tomography (OCT) and fundus autofluorescence, are improving the early detection and monitoring of AMD. These technologies provide high-resolution images of the retina, allowing for more accurate diagnosis and better management of the disease.
- Growing Awareness and Screening Programs: Increased awareness of AMD and the importance of early detection are leading to more widespread screening and diagnosis. Public health initiatives and educational campaigns are helping to identify at-risk populations and encourage regular eye examinations.
- Expansion of Clinical Research: There is a growing focus on clinical research to understand the underlying mechanisms of AMD and develop new therapeutic approaches. Numerous clinical trials are underway to explore the efficacy and safety of emerging treatments, contributing to a robust pipeline of potential therapies.
- Personalized Medicine and Genetic Testing: Advances in personalized medicine and genetic testing are enabling more tailored treatment approaches for AMD patients. By understanding individual genetic risk factors, clinicians can develop more effective treatment plans and potentially prevent the onset of the disease in high-risk individuals.
- Government and Private Sector Investments: Increased funding from government bodies, research institutions, and private sector companies is fuelling advancements in AMD research and treatment. These investments support the development of new therapies, diagnostic tools, and patient care strategies.
Global Age-Related Macular Degeneration Market Segmentation
Market Breakup by Product
- Wet AMD
- Dry AMD
Market Breakup by Drug
- Lucentis
- Eylea
- Avastin
- Others
Market Breakup by Route of Administration
- Intravenous
- Intravitreal
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Age-Related Macular Degeneration Market Overview
The age-related macular degeneration (AMD) market in North America is driven by advanced healthcare infrastructure, significant healthcare expenditure, and a high prevalence of AMD due to the aging population. The region benefits from robust research and development activities, leading to the continuous introduction of innovative therapies such as anti-VEGF injections and gene therapy. Additionally, high awareness levels and regular screening programs contribute to early diagnosis and effective management of AMD. With strong support from regulatory bodies and substantial investments in healthcare, North America is expected to maintain its leading position in the AMD market during the forecast period.
Europe represents a significant market for age-related macular degeneration, characterized by a strong emphasis on medical research and a well-established healthcare system. The region’s market growth is driven by an increasing elderly population, government initiatives to improve healthcare outcomes, and rising investments in medical research and development. Technological advancements in diagnostic imaging, such as optical coherence tomography (OCT), are widely adopted, enhancing the early detection and monitoring of AMD. Europe’s focus on personalized medicine and the development of new therapeutic approaches positions it as a key player in the global AMD market.
The Asia Pacific region is expected to witness the highest growth rate in the global age-related macular degeneration market during the forecast period. Factors such as rapidly improving healthcare infrastructure, increasing healthcare expenditure, and growing awareness of AMD contribute to this growth. The large and aging population in countries like China and Japan creates significant demand for effective AMD treatments. Government initiatives to enhance healthcare access and support for medical research are also driving market expansion. As the region continues to adopt advanced therapies and improve diagnostic capabilities, the Asia Pacific market is set to play a major role in the global AMD landscape.
Latin America is emerging as a promising market for age-related macular degeneration, supported by economic improvements, increasing healthcare investments, and rising awareness of eye health. The region’s growing burden of AMD and other age-related eye conditions is driving the demand for advanced diagnostic and therapeutic solutions. Countries such as Brazil and Mexico are seeing significant healthcare infrastructure development, making innovative treatments more accessible.
The Middle East and Africa are also witnessing growth in the age-related macular degeneration market, driven by improving healthcare infrastructure, economic development, and a growing focus on advanced medical technologies. Governments in the region are investing in healthcare modernization and promoting awareness of AMD. The increasing prevalence of age-related eye conditions and the rising demand for effective diagnostic and therapeutic solutions are fueling market growth.
Global Age-Related Macular Degeneration Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bayer AG
It is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Founded in 1863, Bayer is known for its wide range of products in healthcare and agriculture. Key segments include Pharmaceuticals, Consumer Health, and Crop Science. Major products include Aspirin, Xarelto, Eylea, and Roundup. Bayer is headquartered in Leverkusen, Germany, and operates globally with a significant presence in Europe, North America, and Asia-Pacific.
- Hoffmann-La Roche Ltd.
It is commonly known as Roche, is a Swiss multinational healthcare company that operates in two main divisions: Pharmaceuticals and Diagnostics. Founded in 1896, Roche is a global leader in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. Major products include Avastin, Herceptin, and Rituxan. The Diagnostics division focuses on clinical laboratory and point-of-care diagnostics. Roche is headquartered in Basel, Switzerland, and operates worldwide, with a strong presence in Europe and North America.
- Novartis AG
It is a Swiss multinational pharmaceutical company formed in 1996 through the merger of Ciba-Geigy and Sandoz. Novartis focuses on innovative medicines, generics, and eye care. Its key divisions are Innovative Medicines, Sandoz (generics), and Alcon (eye care). Major products include Cosentyx, Entresto, and Gilenya. Novartis is headquartered in Basel, Switzerland, and has a broad geographic presence, with significant operations in Europe, North America, and Asia-Pacific.
- Regeneron Pharmaceuticals Inc
It is an American biotechnology company that specializes in the discovery, development, and commercialization of medicines for serious medical conditions. Founded in 1988, Regeneron has developed several successful drugs, including Eylea, Dupixent, and Libtayo. The company’s focus areas include ophthalmology, immunology, oncology, cardiovascular and metabolic diseases, and infectious diseases. Regeneron is headquartered in Tarrytown, New York, and operates primarily in North America, with a growing international presence.
About Us:
Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.
Our high-quality, data-driven analyses provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today’s competitive market.
Don’t miss the opportunity to elevate your business intelligence and fortify your strategic planning. Secure your organisation’s future success by acquiring one of our Expert Market Research reports today.
Media Contact:
Company Name: Claight Corporation
Contact Person: Mark, Business Consultant
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
